PL165357B1 - Sposób wytwarzania nowych pochodnych mocznika PL PL - Google Patents
Sposób wytwarzania nowych pochodnych mocznika PL PLInfo
- Publication number
- PL165357B1 PL165357B1 PL90291470A PL29147090A PL165357B1 PL 165357 B1 PL165357 B1 PL 165357B1 PL 90291470 A PL90291470 A PL 90291470A PL 29147090 A PL29147090 A PL 29147090A PL 165357 B1 PL165357 B1 PL 165357B1
- Authority
- PL
- Poland
- Prior art keywords
- compounds
- cholesterol
- formula
- urea derivatives
- methylthio
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/58—Two sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/70—Sulfur atoms
- C07D277/74—Sulfur atoms substituted by carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Sposób wytwarzania nowych pochod- nych mocznika o wzorze przedstawionym na rysunku, w którym R1 oznacza tri(C1 -C4)- alkoksyfenyl,(C1 -C4)alkilo-di(C1 -C4)alkilotio- pirydynyl, (C1 -C4)alkilo-di(C1 -C4)alkilotio- pirymidynyl, a R17 i R18 oznaczaja grupe (C4-C8)alkilowa lub grupe (C1 -C6)alkilofenylo- metylowa i ich sole, znamienny tym, ze drugo- rzedowa amine o wzorze N H R17R18, w którym R1 7 i R1 8 maja wyzej podane znaczenie, pod- daje sie reakcji ze zwiazkiem o wzorze R1 NCO, w którym R1 ma wyzej podane znaczenie. Wzór 1 PL PL
Description
Przedmiotem wynalazku jest sposób wytwarzania nowych pochodnych mocznika, mających zastosowanie jako składniki leków przeznaczonych do hamowania absorpcji cholesterolu w jelitach, obniżania poziomu cholesterolu w surowicy i odwracania procesu arteriosklerozy. Wytwarzane związki są inhibitorami acylo-koenzymu A: acylotransferazy cholesterolowej (ACAT).
Cholesterol konsumowany wraz z pożywieniem (cholesterol pokarmowy) jest absorbowany w postaci wolnego cholesterolu przez komórki śluzówki jelita cienkiego. Tam zachodzi jego estryfikacja, w której pośredniczy enzym ACTA, po czym wnika do cząstek znanych jako chylomikrony i przechodzi do krwioobiegu. Chylomikrony są cząstkami, do których „pakowany jest cholesterol pokarmowy i za pośrednictwem których wprowadzany jest do krwioobiegu. Przez hamowanie działania ACTA związki wytwarzane sposobem według wynalazku, zapobiegają absorpcji cholesterolu pokarmowego w jelitach, obniżając przez to poziom cholesterolu w surowicy. Są zatem użyteczne w zapobieganiu arteriosklerozie, atakom serca i udarom.
Poprzez hamowanie aktywności ACTA, związki wytwarzane sposobem według wynalazku umożliwiają usuwanie cholesterolu ze ścian naczyń krwionośnych. Działanie to sprawia, że związki te są użyteczne do spowolniania lub odwracania procesu arteriosklerozy, jak również do zapobiegania atakom serca i udarom.
Inne inhibitory ACTA są ujawnione w opisach patentowych Stanów Zjednoczonych Ameryki nr nr 4716 175 i 4743 605 (powstały z podziału patentu nr 4 716 175) oraz w publikacjach europejskich zgłoszeń patentowych nr nr EP 0242 610, 0245687 oraz 0252524. Niektóre moczniki i tiomoczniki wykazujące aktywność jako środki hamujące sklerozę naczyń krwionośnych są opisane w opisie patentowym Stanów Zjednoczonych Ameryki nr4 623 662.
Przedmiotem wynalazku jest sposób wytwarzania nowych pochodnych mocznika o wzorze przedstawionym na rysunku, w którym R1 oznacza tri(C1-C 4)alkoksyfenyl, (C1-C 4)alkilo-di(C1C4)alkilotiopirydynyl, (C1-C4)alkilo-di-(C1-C4)alkilotiopirymidynyl, a Rv i Rw oznaczają grupę (C 4-C8)alkilową lub grupę (C1-C6)alkilofenylometylową.
Sposób według wynalazku polega na poddaniu drugorzędowej aminy o wzorze NHR^R^, w którym R17 i Rw mają wyżej podane znaczenie, reakcji ze związkiem o wzorze R1NCO, w którym R1 ma wyżej podane znaczenie. Otrzymany produkt w razie potrzeby przekształca się w sól.
Korzystnymi związkami wytwarzanymi zgodnie z wynalazkiem są te, w których R1 oznacza grupę 2,4,6-trójmetoksyfenylową, 2-metylo-4,6-dwu(metylotio)pirymidyn-5-ylową i 6-metylo-2,4-dwumetylotio/pirydyn-3-ylową.
Kompozycje farmaceutyczne zawierające omawiane związki są przeznaczone do hamowania aktywności enzymu ACAT, hamowania jelitowej absorpcji cholesterolu, odwracania lub spowolniania procesu arteriosklerozy i obniżania stężenia cholesterolu w surowicy ssaków, również ludzi. Kompozycje zawierają taką ilość związku czynnego lub dopuszczalnej w farmacji soli tego związku, która skutecznie hamuje aktywność enzymu ACTA lub absorpcję jelitową cholesterolu, odwraca lub spowalnia proces arteriosklerozy i obniża stężenie cholesterolu w surowicy a ponadto zawiera dopuszczalny w technologii farmaceutycznej nośnik.
165 357
Przykładami dopuszczalnych w technologii farmaceutycznej soli addycyjnych otrzymanych związków z kwasami są sole utworzone z kwasem solnym, p-toluenosulfonowym, fumarowym, cytrynowym, bursztynowym, salicylowym, szczawiowym, bromowodorowym, fosforowym, metanosulfonowym, winowym, dwutoluilowinowym i migdałowym.
Pochodne mocznika wytwarza się jak wspomniano w reakcji drugorzędowej aminy o wzorze NHR17R18 ze związkiem o wzorze R1NCO. Reakcję prowadzi się zazwyczaj w temperaturze otoczenia w rozpuszczalniku węglowodorowym, takim jak heksan. Drugorzędowe aminy o wzorze NHR17r18 można wytwarzać różnymi metodami znanymi w chemii, na przykład według sposobu podanego w „Vogel's Textbook of Practical Organic Chemistry, Longman Inc., New York, str. 564 - 575 (4 wyd. 1978).
Nowe związki otrzymane sposobem według wynalazku i ich dopuszczalne w farmacji sole są użyteczne jako inhibitory acylo-koenzymu A: acylotransferazy cholesterolowej (ACAT). Związki te hamują jelitową absorpcję cholesterolu u ssaków i są użyteczne do leczenia wysokiego poziomu cholesterolu w surowicy ssaków, w tym również ludzi. Leczenie to dotyczy zarówno zapobiegania jak i obniżania wysokiego poziomu cholesterolu we krwi. Związki te mogą być podawane osobom wymagającym leczenia wieloma konwencjonalnymi drogami podawania, doustnie, parenteralnie lub miejscowo. W zasadzie, związki te będą podawane doustnie lub parenteralnie, w dawkach od 0,5 do około 30 mg/kg wagi ciała pacjenta/dzień, korzystnie w dawkach od około 0,08 do 5 mg/kg. Dla dorosłego człowieka o średniej wadze (70 kg) zazwyczaj stosowana dawka będzie zatem wynosić od około 3,5 do około 2000 mg dziennie. Pewne różnice w dawkowaniu będą jednak niezbędne, w zależności od stanu zdrowia leczonego pacjenta i aktywności zastosowanego związku. W każdym przypadku, osoba odpowiedzialna za leczenie określi odpowiednią dawkę dla danego pacjenta.
Związek czynny lub dopuszczalną w farmacji sól tego związku można podawać jako czysty związek lub w połączeniu z dopuszczalnymi w technologii farmaceutycznej nośnikami, w dawce pojedynczej lub w dawkach podzielonych. Odpowiednimi nośnikami farmaceutycznymi są tu obojętne, stałe rozcieńczalniki lub napełniacze, sterylne roztwory wodne oraz różne rozpuszczalniki organiczne. Wytworzone kompozycje farmaceutyczne podaje się dogodnie w różnych formach dawkowania, takich jak tabletki, proszki, pastylki, syropy, roztwory injekcyjne i podobne. Jeśli to potrzebne, takie kompozycje farmaceutyczne mogą zawierać środki pomocnicze, takie jak cytrynian sodowy, węglan wapniowy czy fosforan wapniowy, jak również różne środki rozsadzające, takie jak skrobię, kwas alginowy oraz niektóre kompleksy krzemianów oraz środki wiążące, takie jak poliwinylopirolidon, sacharozę, żelatynę lub gumę akacjową. Ponadto, do celów tabletkowania często stosuje się środki poślizgowe, takie jak stearynian magnezowy, laurylo-siarczan sodowy i talk. Stałe kompozycje o podobnym składzie można również stosować do napełniania miękkich i twardych kapsułek żelatynowych. Korzystnymi środkami pomocniczymi stosowanymi w tym przypadku są laktoza lub cukier mlekowy oraz glikole polistyrenowe o wysokim ciężarze cząsteczkowym. Przy przygotowaniu związków wodnych lub eliksirów do podawania doustnego łączy się podstawowy składnik czynny z różnymi środkami słodzącymi lub zapachowymi, substancjami barwnymi lub barwnikami i tam, gdzie to potrzebne, ze środkami emulgującymi lub suspendującymi oraz z rozcieńczalnikami, takimi jak woda, etanol, glikol propylenowy, gliceryna i ich kombinacje.
Do celów podawania parenteralnego stosuje się roztwory związku czynnego lub dopuszczalnej w farmacji soli tego związku w oleju sezamowym lub arachidowym, w wodnym roztworze glikolu propylenowego lub w sterylnym roztworze wodnym. Takie roztwory wodne powinny być odpowiednie do potrzeb, właściwie buforowane a ciekły rozcieńczalnik powinien być uprzednio doprowadzany do izotoniczności odpowiednią ilością soli fizjologicznej lub glukozy. Rioztwory te są przeznaczone zwłaszcza do podawania dożylnego, domięśniowego, podskórnego i dootrzewnowego. Stosowane w tego typu formach sterylne media wodne są łatwo osiągalne znanymi standardowymi technikami.
Aktywność związków wytwarzanych sposobem według wynalazku jako inhibitorów ACAR można oznaczyć różnymi standardowymi testami biologicznymi lub farmakologicznymi. Przykładowo dla oznaczenia aktywności hamującej ACTA stosuje się następującą procedurę. Enzym ACAT oznacza się w mikrosomach wyizolowanych ze szczurów rasy Spraque-Dawley karmionych
165 357 specjalną paszą według metody Bilheimer'a J. T. (Meth. Enzymol., 111, str. 286 - 293, 1985) z niewielkimi modyfikacjami. Przed użyciem mikrosomy z wątroby preparuje się przez wirowanie różnicowe i przemycie buforem do oznaczeń. Oznaczana mieszanina zawierała 25gl BSA (40 mg/ml), 30/g roztworu mikrosomów z wątroby szczura (100 gg mikrosomalnego białka), 20 gl buforu do oznaczeń (0,1 M K2PO4 1,0 mM zredukowanego glutationu, pH 7,4), 20gg cholesterolu w 100gl 0,6 procentowego Tritenu WR-1339 w buforze do oznaczeń i 5 gl roztworu badanego związku rozpuszczonego w 100 procentowym DMSO (całkowita objętość - 180 pl). Mieszaninę tę inkubowano przez 30 minut w temperaturze 37°C. Reakcję inicjowano przez dodanie 20 pl 14COleile-CoA (100 pM, 2000dpm/nmol) i kontynuowano przez 15 minut w temperaturze 37CC. Reakcję zatrzymywano przez dodanie 1 ml EtOH. Lipidy ekstrahowano do 4 ml heksanu. Ilość 5 ml tego ekstraktu suszono w atmosferze azotu i zawieszano w 100pl chloroformu. Ilość 50pml zawiesiny chloroformowej nakraplano na aktywowaną ciepłem płytkę TLC i rozwijano w układzie: heksan : eter dietylowy : kwas octowy (85:15:1 objętościowo). Radioaktywność wprowadzoną do estrów cholesterolu oznacza się ilościowo w analizatorze liniowym TLC Bertholda LB2842. Aktywność hamująca ACTA wyliczono w stosunku do próby kontrolnej z DMSO.
Aktywność omawianych związków w hamowaniu jelitowej absorpcji cholesterolu można oznaczać metodą opisaną przez Melchoir'a i Harwell'a (J. Lipid. Res., 26, 306 - 315 (1985)).
Sposób według wynalazku zilustrowany jest następującymi przykładami. Temperatury topnienia nie są korygowane. Pomiarów widm protonowego rezonansu magnetycznego jądrowego (1HNMR) i magnetycznego rezonansu jądrowego C15 (C^NMR) dokonywano w roztworach w deuterochloroformie (CDCI3) a pozycje pików wyrażano w częściach na milion (ppm) w dół od tetrametylosilanu (TMS). Kształty pików oznaczono następująco: s - singlet, d - dublet, t - triplet, q - kwartet, m - multiplet, br - szeroki, c - złożony.
Przykład I. N-(2,4,6-Trójmetoksyfenylo)-N'-[4-(3-metylobutylo)fenylometylo]-N'-heptylomocznik.
Mieszaninę 209 mg (1 milimol) 2,4,6-trójmetoksyfenyloizocyjanianu, 275 mg N-heptylo-4-(3metylobutylo)benzyloaminy i 10 ml chlorku metylenowego miesza się w temperaturze pokojowej przez dobę. Następnie mieszaninę reakcyjną zatęża się pod zmniejszonym ciśnieniem. Po chromatografii na 100g żelu krzemionkowego z eluowaniem układem: heksan-octan etylowy (1:1) uzyskuje się 320 mg produktu (66% wydajności).
1HNMR (CDCI3): δ 0,81 - 0,96 (c) i 0,92 (d) (całość 9K), 1,27 (c, 9H), 1,44 - 1,68 (c, 4H), 2,6 (t, 2H), 3,33 (t, 2H), 3,75 (s, 6H), 3,77 (s, 3H), 4,55 (s, 2H), 5,55 (s, 1H), 6,11 (s, 2H), 7,15 (d, 2H), 7,24 (d, 2H). IR (CHCI3): 1654 cm'\
Przykład II. N-(2,4,6-Trójmetoksyfenylo)-N'-[4-(2,2-dimetylopropylo)fenylo]-N-heptylomocznik.
Tytułowy związek wytwarza się w sposób opisany w przykładzie I, stosując 760 mg (3,63 milimola) 2,4,6-trójmetoksyfenyloizocyjanianu, 1,0 g (3,63 milimola) N-heptylo-4-(2,2-dimetylopropylo)benzyloaminy i 20 ml chlorku metylenowego. Uzyskuje się 1,25 g produktu (71% wydajności).
Ή NMR (CDCl3): δ 0,82 - 0,95 (c) i 0,89 (s) (całość 12H), 1,27 (c, 8H), 1,61 (c, 2H), 2,48 (s, 2H), 3,34 (t, 2H), 3,76 (s, 6H), 3,78 (s, 3H), 4,57 (s, 2H), 5,59 (s, 1H), 6,12 (s, 2H), 7,1 (d, 2H), 7,23 (d, 2H). IR (CHCl3): 1657 cm!
Przykład III. N'-[2,4-dwu(metylotio)-6-metylopirymidyn-3-ylo]-N-[4-(3-metylobutylo)benzylo]-N-cykloheptylomocznik.
A. Izocyjanian 2,4-dwu(metylotio)-6-metylopirydyn-3-ylo.
Roztwór 800 mg (4 milimoli) 2,4-dwu(metylotio)-3-amino-6-metylopirydyny i 0,4 ml (2,3 milimoli) chloromrówczanu trójchlorometylu w 20 ml bezwodnego dioksanu ogrzewa się przez noc w temperaturze wrzenia pod chłodnicą zwrotną. Mieszaninę reakcyjną chłodzi się i sączy, a przesącz odparowuje się w próżni do sucha, otrzymując 730 mg tytułowego związku (81% wydajności) jako zabarwionego brązowo ciała stałego.
B. N'-[2,4-dwu(metylotio)-6-metylopirydyn-3-ylo]-N-[4-(3-metylobutylo)benzylo]-N-cykloheptylomocznik.
Roztwór 135 mg (0,6 milimola) izocyjanianu z przykładu IIIA i 164 mg (0,6 milimoli) N-cykloheptylo-4-(3-metylobutylo)benzyloaminy w 15 ml chlorku metylenu ogrzewa się przez noc
165 357 w atmosferze azotu, w temperaturze wrzenia pod chłodnicą zwrotną. Mieszaninę reakcyjną chłodzi się do temperatury pokojowej i odparowuje w próżni. Pozostałość chromatografuje się na 200 g żelu krzemionkowego, eluuje się 7:3 heksanem/octanem etylu, otrzymuje się 140 mg (32% wydajności) tytułowego związku jako prawie białego ciała stałego.
1HNMR (CDCls): δ 0,92 (d, 6H), 1,39- 1,74 (c, 13H), 1,98 (m,2H), 2,37 (s, 3H), 2,44 (s,6H),
2.59 (t, 2H), 4,37 (m, 1H), 4,50 (s, 2H), 5,47 (s, 1H), 6,57 (s, 1H), 7,18 (d, 2H), 7,32 (d, 2H).
IR (CHCla): 1921, 2853, 1650, 1560, 1469 cm’1.
W analogiczny sposób do sposobu postępowania z przykładu III otrzymano związki:
N'-[2,4-dwu(metylotio)-6-metylopirydyn-3-ylo]-N-[/4-(2,2-d\wimetylopropylo)benzylo]-N-cykloheptylomocznik. 70% wydajności.
1H NMR (CDCls): δ 0,88 (s, 9H), 1,39 -1,74 (c, 10H), 1,99 (m, 2H), 2,33 (s, 3H), 2,44 (2s, 6 H), 2,48 (s, 2H), 4,38 (m, 1H), 4,52 (s, 2H), 5,46 (s, 1H), 6,57 (s, 1H), 7,13 (d, 2H), 7,31 (d, 2H).
IR (CHCI3): 2922, 2853, 1651, 1561, 1470 cm.
N'-[2-metylo-4,6-dwu(metylotio)pirymidyn-5-ylo]-N-[4-(3-metylobutylo)benzylo]-N-cykloheptylomocznik. 72% wydajności.
1H NMR (CDCI3): δ 0,92 (d, 6 H), 1,40 - 1,75 (c, 13H), 1,98 (m, 2H), 2,44 (s, 6 H), 2,55 (s, 3H),
2.60 (t, 2H), 4,37 (m, 1H), 4,51 (s, 2H), 5,37 (s, 1H), 7,20 (d, 2H), 7,31 (d, 2H).
IR (CHCI3): 2920, 2853, 1651, 1467 cm'1.
N'-[2-metylo-4,6-dwu(metylotio)pirymidyn-5-ylo]-N-[4-(2,2-dwumetylopropylo)benzylo--N-cykloheptylomocznik. 70% wydajności.
1H NMR (CDCI3): δ 0,87 (t, 3H), 1,21-1,82 (c, 24H), 2,28 (m, 2H), 2,51 (s, 6 H), 6,69 (s, 1H), 8,64 (s, 1H).
IR (CHCla): 2922, 2850, 1682, 1452, 1405, 1358 cm'1.
N'-[2-metylo-4,6-dwu(metylotio)pirymidyn-5-ylo]-N-[4-(3-metylobutylo)benzylo]-N-heptylomocznik. 43% wydajności.
1H NMR (CDCI3): δ 0,86 (m), 0,92 (d) (całkowity 9H), 1,20 - 1,72 (d, 13H), 2,47 (s, 6 H), 2,57 (s), 2,60 (t), (całkowity 5H), 3,34 (t, 2H), 4,56 (s, 2H), 5,51 (s, 1H), 7,15 (d, 2H), 7,24 (d, 2H).
IR (CHCl3): 2920, 2850, 1659, 1468, 1415 cm'1.
N'-[-,4-dwu(metylotio)-6-metylopiΓydyn-3-ylo--N-[4-(3-metylobutylo)benzylo--N-heptylomocznik. 32% wydajności.
1HNMR (CDCl3): δ 0,87 (m), 0,92 (d) (całkowity 9H), 1,19 -1,72 (c, 13H), 2,37 (s, 3H), 2,46 (s, 3H), 2,48 (s, 3H), 2,59 (t, 2H), 3,34 (t, 2H), 4,58 (s, 2H), 5,61 (s, 1H), 6,61 (s, 1H), 7,17 (d, 2H), 7,27 (d, 2H).
IR (CDCI3): 2922, 2852, 1656, 1558, 1467 cm'1.
Wzór 1
Departament Wydawnictw UP RP. Nakład 90 egz. Cena 10 000 zł
Claims (1)
- Zastrzeżenie patentoweSposób wytwarzania nowych pochodnych mocznika o wzorze przedstawionym na rysunku, w którym R1 oznacza tri(C1-C4)alkoksyfenyl, (C1-C4)alkilo-di(C1-C4)alkilotiopirydynyl, (C1-C4)alkilo-di(C1-C4)alkilotiopirymidynyl, a R17 i Rw oznaczają grupę (C4-Ca)alkilową lub grupę (C1-C6)alkilofenylometylową i ich sole, znamienny tym, że drugorzędową aminę o wzorze NHR R , w którym R 1 R mają wyżej podane znaczenie, poddaje się reakcji ze związkiem o wzorze R1NCO, w którym R1 ma wyżej podane znaczenie.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1989/004033 WO1991004027A1 (en) | 1989-09-15 | 1989-09-15 | New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat) |
Publications (2)
Publication Number | Publication Date |
---|---|
PL291470A1 PL291470A1 (en) | 1992-07-13 |
PL165357B1 true PL165357B1 (pl) | 1994-12-30 |
Family
ID=22215232
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL90291470A PL165357B1 (pl) | 1989-09-15 | 1990-09-14 | Sposób wytwarzania nowych pochodnych mocznika PL PL |
PL29147290A PL291472A1 (en) | 1989-09-15 | 1990-09-14 | Method of obtaining novel derivatives of n-aryl and n-heteroaryl amide |
PL90286899A PL165370B1 (pl) | 1989-09-15 | 1990-09-14 | Sposób wytwarzania nowych pochodnych N-arylo-i N-heteroaryloamidu PL PL |
PL29147190A PL291471A1 (en) | 1989-09-15 | 1990-09-14 | Method of obtaining acids of predetermined general formula |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL29147290A PL291472A1 (en) | 1989-09-15 | 1990-09-14 | Method of obtaining novel derivatives of n-aryl and n-heteroaryl amide |
PL90286899A PL165370B1 (pl) | 1989-09-15 | 1990-09-14 | Sposób wytwarzania nowych pochodnych N-arylo-i N-heteroaryloamidu PL PL |
PL29147190A PL291471A1 (en) | 1989-09-15 | 1990-09-14 | Method of obtaining acids of predetermined general formula |
Country Status (24)
Country | Link |
---|---|
EP (2) | EP0609960B1 (pl) |
JP (1) | JPH0825974B2 (pl) |
KR (1) | KR930011303B1 (pl) |
CN (1) | CN1050183A (pl) |
AT (2) | ATE121730T1 (pl) |
AU (1) | AU652345B2 (pl) |
CA (1) | CA2025301C (pl) |
DD (1) | DD298092A5 (pl) |
DE (2) | DE69032981T2 (pl) |
DK (2) | DK0418071T3 (pl) |
EG (1) | EG19358A (pl) |
ES (2) | ES2127878T3 (pl) |
FI (1) | FI111362B (pl) |
GR (1) | GR3029826T3 (pl) |
HU (1) | HUT70027A (pl) |
IE (1) | IE66324B1 (pl) |
IL (3) | IL95610A (pl) |
MX (1) | MX22406A (pl) |
NO (1) | NO904022L (pl) |
NZ (1) | NZ235323A (pl) |
PL (4) | PL165357B1 (pl) |
PT (1) | PT95310B (pl) |
WO (1) | WO1991004027A1 (pl) |
ZA (1) | ZA907346B (pl) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004027A1 (en) * | 1989-09-15 | 1991-04-04 | Pfizer Inc. | New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat) |
US5668136A (en) * | 1990-09-25 | 1997-09-16 | Eisai Co., Ltd. | Trisubstituted benzene derivatives, composition and methods of treatment |
CA2096970C (en) * | 1990-11-26 | 1998-07-14 | Masakazu Sato | Anilide derivative |
CA2099564A1 (en) * | 1991-01-31 | 1992-08-01 | Sarah E. Kelly | Synthesis of intermediates in the preparation of acat inhibitors |
FR2674522B1 (fr) * | 1991-03-26 | 1993-07-16 | Lipha | Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant. |
JPH0776215B2 (ja) * | 1991-04-26 | 1995-08-16 | フアイザー・インコーポレイテツド | 4−アリール−3−(ヘテロアリールウレイド)キノリン誘導体 |
US5238935A (en) * | 1991-05-20 | 1993-08-24 | Schering Corporation | N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme A: cholesterol acyl transferase |
US5124337A (en) * | 1991-05-20 | 1992-06-23 | Schering Corporation | N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase |
ES2125325T3 (es) * | 1992-01-23 | 1999-03-01 | Pfizer | Derivados de 4-fenil-3-(heteroarilureido)-1,2-dihidro-2-oxoquinolina como agentes antihipercolesterolemicos y antiateroscleroticos. |
FR2687402B1 (fr) * | 1992-02-14 | 1995-06-30 | Lipha | Nouveaux azaindoles, procedes de preparation et medicaments les contenant. |
JPH05320143A (ja) * | 1992-03-18 | 1993-12-03 | Mochida Pharmaceut Co Ltd | 新規ピリミジン誘導体 |
WO1993024458A1 (en) * | 1992-05-28 | 1993-12-09 | Pfizer Inc. | New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (acat) |
JP3612328B2 (ja) * | 1992-07-20 | 2005-01-19 | エーザイ株式会社 | ベンゼン誘導体 |
US5239082A (en) * | 1992-08-03 | 1993-08-24 | Warner-Lambert Company | Sulfonamide tetrazole ACAT inhibitors |
US5565472A (en) * | 1992-12-21 | 1996-10-15 | Pfizer Inc. | 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents |
DE4401893A1 (de) * | 1994-01-24 | 1995-07-27 | Bayer Ag | Substituierte Arylharnstoffe |
US5491152A (en) * | 1994-03-23 | 1996-02-13 | The Du Pont Merck Pharmaceutical Company | Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis |
AU2935895A (en) * | 1994-07-15 | 1996-02-16 | Takeda Chemical Industries Ltd. | Tricyclic compounds, their production and use |
US6133326A (en) | 1994-08-31 | 2000-10-17 | Pfizer Inc | Compositions and methods for decreasing sebum production |
WO1996026925A1 (fr) * | 1995-03-01 | 1996-09-06 | Banyu Pharmaceutical Co., Ltd. | Derives de l'arylthioacetamide |
JP4191269B2 (ja) | 1996-05-17 | 2008-12-03 | 興和株式会社 | 新規なアニリド化合物及びこれを含有する医薬 |
CA2308428A1 (en) | 1997-11-03 | 1999-05-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
EP1473292A1 (en) * | 1997-11-03 | 2004-11-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
CA2321237A1 (en) | 1998-02-25 | 1999-09-02 | Masami Muraoka | Pyridone derivatives and process for producing the same |
US6452008B2 (en) | 1998-02-25 | 2002-09-17 | Sumitomo Pharmaceuticals Company, Limited | Pyridone derivatives and process for preparing the same |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
WO2000050425A1 (en) | 1999-02-22 | 2000-08-31 | Boehringer Ingelheim Pharmaceuticals, Inc. | Polycyclo heterocyclic derivatives as antiinflammatory agents |
JP4820488B2 (ja) | 1999-03-12 | 2011-11-24 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症薬として有用な化合物 |
JP2002539206A (ja) | 1999-03-12 | 2002-11-19 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症剤としての芳香族複素環化合物 |
ATE312823T1 (de) | 1999-07-09 | 2005-12-15 | Boehringer Ingelheim Pharma | Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen |
MXPA02004594A (es) | 1999-11-16 | 2002-10-23 | Boehringer Ingelheim Pharma | Derivados de urea como agentes anti-inflamatorios. |
US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
GEP20043286B (en) | 2000-02-02 | 2004-07-26 | Warner Lambert Co | Dual Inhibitors of Cholesteryl Ester and Wax Ester Synthesis for Sebaceous Gland Disorders |
US6608052B2 (en) | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
DE10050663A1 (de) † | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
CA2445003A1 (en) | 2001-05-16 | 2002-11-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
JP2004531571A (ja) | 2001-05-25 | 2004-10-14 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物 |
US7074805B2 (en) | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
ES2319886T3 (es) * | 2002-02-20 | 2009-05-14 | Abbott Laboratories | Compuestos azabiciclicos condensados que inhiben el sutipo 1 del receptor valinoide (vr1). |
ATE386030T1 (de) | 2002-02-25 | 2008-03-15 | Boehringer Ingelheim Pharma | 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen |
CA2744893A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
WO2004007459A2 (en) * | 2002-07-12 | 2004-01-22 | Janssen Pharmaceutica N.V. | Naphthol, quinoline and isoquinoline-derivatives as modulators of vanilloid vr1 receptor |
US6933311B2 (en) | 2003-02-11 | 2005-08-23 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
CA2547518A1 (en) | 2003-12-12 | 2005-06-30 | Wyeth | Quinolines useful in treating cardiovascular disease |
MXPA06007667A (es) | 2004-01-06 | 2006-09-01 | Novo Nordisk As | Heteroaril-ureas y su uso como activadores de glucocinasa. |
ME01267B (me) | 2004-05-06 | 2013-06-20 | Warner Lambert Co | 4-fenilaminokinazolin-6-ilamidi |
JPWO2006003974A1 (ja) | 2004-06-30 | 2008-04-17 | 興和株式会社 | 環状ジアミン誘導体の製造法 |
ATE547396T1 (de) | 2005-07-08 | 2012-03-15 | Novo Nordisk As | Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren |
WO2007006760A1 (en) | 2005-07-08 | 2007-01-18 | Novo Nordisk A/S | Dicycloalkyl urea glucokinase activators |
EP1904467B1 (en) | 2005-07-14 | 2013-05-01 | Novo Nordisk A/S | Urea glucokinase activators |
MX2008001033A (es) | 2005-07-27 | 2008-03-19 | Hoffmann La Roche | Derivados de 4-ariloxi quinolina como moduladores de 5-ht6. |
US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
TW200824687A (en) | 2006-08-25 | 2008-06-16 | Abbott Lab | Compounds that inhibit TRPV1 and uses thereof |
CN101516839A (zh) * | 2006-09-25 | 2009-08-26 | 贝林格尔.英格海姆国际有限公司 | 调节cb2受体的化合物 |
EP2134678A2 (en) | 2006-12-20 | 2009-12-23 | Abbott Laboratories | N-(5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain |
US8138185B2 (en) | 2007-01-09 | 2012-03-20 | Novo Nordisk A/S | Urea glucokinase activators |
US8318778B2 (en) | 2007-01-11 | 2012-11-27 | Novo Nordisk A/S | Urea glucokinase activators |
CA2719018A1 (en) | 2008-03-20 | 2009-09-24 | Abbott Laboratories | Methods for making central nervous system agents that are trpv1 antagonists |
DK2509961T3 (en) | 2009-12-11 | 2016-05-17 | Autifony Therapeutics Ltd | Imidazolidinedione derivatives |
EP2649066B1 (en) | 2010-12-06 | 2015-10-21 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
JP6008953B2 (ja) | 2011-06-07 | 2016-10-19 | アウトイフオンイ トヘラペウトイクス リミテッド | Kv3阻害剤としてのヒダントイン誘導体 |
US9422252B2 (en) | 2012-05-22 | 2016-08-23 | Autifony Therapeutics Limited | Triazoles as Kv3 inhibitors |
CN104334548A (zh) | 2012-05-22 | 2015-02-04 | 奥蒂福尼疗法有限公司 | 作为kv3抑制剂的乙内酰脲衍生物 |
CN112040945A (zh) | 2018-06-12 | 2020-12-04 | Vtv治疗有限责任公司 | 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途 |
CN109553591B (zh) * | 2019-01-15 | 2020-12-15 | 山东安信制药有限公司 | 一种富马酸喹硫平中间体的制备方法 |
GB201919213D0 (en) * | 2019-12-23 | 2020-02-05 | Ucb Biopharma Sprl | Dihydrocyclopenta-Isoquinoline-Sulfanamide derivatives compounds |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL125255C (pl) * | 1964-07-31 | |||
CH500980A (de) * | 1966-01-28 | 1970-12-31 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Amiden aliphatischer Carbonsäuren |
US3555035A (en) * | 1966-01-28 | 1971-01-12 | Geigy Chem Corp | N-(substituted pyridyl) linolamides and -linolenamides |
CH491112A (de) * | 1966-01-28 | 1970-05-31 | Geigy Ag J R | Verfahren zur Herstellung von neuen Amiden aliphatischer Carbonsäuren |
US5142056A (en) * | 1989-05-23 | 1992-08-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US4722927A (en) * | 1986-04-28 | 1988-02-02 | Warner-Lambert Company | Pyrimidine amides of oleic or linoleic acid, composition containing them and their use as inhibitors of acyl-CoA cholesterol acyltransferase |
US4716175A (en) * | 1987-02-24 | 1987-12-29 | Warner-Lambert Company | Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase |
US5238908A (en) * | 1989-08-31 | 1993-08-24 | Rohm And Haas Company | Herbicidal glutaramic acids and derivatives |
DE3929507A1 (de) * | 1989-09-06 | 1991-03-07 | Bayer Ag | Substituierte amino-pyridine |
WO1991004027A1 (en) * | 1989-09-15 | 1991-04-04 | Pfizer Inc. | New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat) |
-
1989
- 1989-09-15 WO PCT/US1989/004033 patent/WO1991004027A1/en unknown
- 1989-09-15 MX MX2240690A patent/MX22406A/es unknown
-
1990
- 1990-09-07 IL IL9561090A patent/IL95610A/en not_active IP Right Cessation
- 1990-09-13 DK DK90310009.7T patent/DK0418071T3/da active
- 1990-09-13 AT AT90310009T patent/ATE121730T1/de not_active IP Right Cessation
- 1990-09-13 DK DK94200437T patent/DK0609960T3/da active
- 1990-09-13 CA CA002025301A patent/CA2025301C/en not_active Expired - Fee Related
- 1990-09-13 PT PT95310A patent/PT95310B/pt not_active IP Right Cessation
- 1990-09-13 EG EG54590A patent/EG19358A/xx active
- 1990-09-13 DE DE69032981T patent/DE69032981T2/de not_active Expired - Fee Related
- 1990-09-13 ES ES94200437T patent/ES2127878T3/es not_active Expired - Lifetime
- 1990-09-13 DE DE69018908T patent/DE69018908T2/de not_active Expired - Fee Related
- 1990-09-13 EP EP94200437A patent/EP0609960B1/en not_active Expired - Lifetime
- 1990-09-13 AT AT94200437T patent/ATE177082T1/de not_active IP Right Cessation
- 1990-09-13 ES ES90310009T patent/ES2071033T3/es not_active Expired - Lifetime
- 1990-09-13 EP EP90310009A patent/EP0418071B1/en not_active Expired - Lifetime
- 1990-09-14 PL PL90291470A patent/PL165357B1/pl unknown
- 1990-09-14 JP JP2245969A patent/JPH0825974B2/ja not_active Expired - Fee Related
- 1990-09-14 NZ NZ235323A patent/NZ235323A/xx unknown
- 1990-09-14 PL PL29147290A patent/PL291472A1/xx unknown
- 1990-09-14 CN CN90108294A patent/CN1050183A/zh active Pending
- 1990-09-14 PL PL90286899A patent/PL165370B1/pl unknown
- 1990-09-14 NO NO90904022A patent/NO904022L/no unknown
- 1990-09-14 ZA ZA907346A patent/ZA907346B/xx unknown
- 1990-09-14 PL PL29147190A patent/PL291471A1/xx unknown
- 1990-09-14 FI FI904537A patent/FI111362B/fi active IP Right Grant
- 1990-09-14 HU HU9302945A patent/HUT70027A/hu unknown
- 1990-09-14 AU AU62553/90A patent/AU652345B2/en not_active Ceased
- 1990-09-14 KR KR1019900014554A patent/KR930011303B1/ko not_active IP Right Cessation
- 1990-09-14 IE IE333690A patent/IE66324B1/en not_active IP Right Cessation
- 1990-09-27 DD DD90343971A patent/DD298092A5/de not_active IP Right Cessation
-
1994
- 1994-07-14 IL IL11032494A patent/IL110324A0/xx unknown
- 1994-07-14 IL IL11032194A patent/IL110321A0/xx unknown
-
1999
- 1999-03-30 GR GR990400917T patent/GR3029826T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL165357B1 (pl) | Sposób wytwarzania nowych pochodnych mocznika PL PL | |
US4315007A (en) | 4-Amino-6,7-dimethoxyquinazol-2-yl alkylenediamines | |
EP0540544B1 (en) | Benzoic acid substituted derivatives having cardiovascular activity | |
US5254589A (en) | Sulfonyl urea and carbamate ACAT inhibitors | |
US4933447A (en) | Quinoline derivatives | |
BG99188A (bg) | Нови производни на n-арил и n-хетероарилуреа като инхибитори на ацил коензим а:холестерол ацил-трансфераза (асат) | |
EP0742208A1 (en) | 2-Ureido-benzamide derivatives | |
US5565472A (en) | 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents | |
EP0168005B1 (en) | Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same | |
EP0623112B1 (en) | 4-Phenyl-3-(heteroarylureido)-1,2-dihydro-2-oxoquinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents | |
EP0326106A2 (en) | Alkylene diamines | |
EP0384320A1 (en) | Antihyperlipidemic and anti-atherosclerotic trisubstituted urea compounds | |
IE910780A1 (en) | Urea derivatives, their production, and pharmaceutical¹compositions containing them | |
JPS6330908B2 (pl) | ||
JP3053418B2 (ja) | 新規の置換アルキルピペリジンとコレステロール合成阻害剤としてのその用途 | |
US4994465A (en) | Antihyperlipidemic and antiatherosclerotic trisubstituted urea compounds | |
JPH05186458A (ja) | 新規なベンゾピラン誘導体 | |
EP0247345A2 (en) | 1,4-Dihydropyridine-3,5-dicarboxylates incorporating an alkyleneaminoalkylene-heteroatom moiety | |
US5258405A (en) | Urea derivatives and salts thereof in method for inhibiting the ACAT enzyme | |
US6083971A (en) | Certain oxopyrolo-pyrrole derivatives having thrombin inhibiting activity | |
US3959281A (en) | Piperazino substituted coumarin derivatives | |
KR20000029897A (ko) | 약학적활성화합물및그것의사용방법 | |
US4948806A (en) | Antihyperlipidemic and antiatherosclerotic compounds and compositions | |
Klasek et al. | Reaction of 3‐aminoquinoline‐2, 4‐diones with isocyanates. Synthesis of novel 3‐(3′‐alkyl/arylureido) quinoline‐2, 4‐diones and their cyclic carbinolamide isomers | |
US4999373A (en) | Antihyperlipidemic and antiatherosclerotic compounds and compositions |